<DOC>
	<DOCNO>NCT00501787</DOCNO>
	<brief_summary>In recent prospective study evaluate efficacy 1700 mg/day metformin first-line approach infertile anovulatory patient PCOS , identify predictor metformin efficacy . Our analysis demonstrate body mass index ( BMI ) insulin resistance strong predictor ovulation pregnancy . In particular , adjust data insulin resistance , trend reduce effectiveness observe increase BMI . On hand , adjust data BMI , trend improve efficacy detect high insulin resistance degree . To date , dose-finding study currently available literature evaluate best dose metformin administer . In addition , data regard best protocol metformin treatment also available . However , order reduce drug-related side effect incidence due start-up syndrome , metformin generally administrate meal incremental weekly dos maximum dosage range 500 2550 mg daily ; dos reduce side effect appear . This commonly accept protocol support scientific evidence . The aim present study evaluate clinical setting compliance , safety effectiveness two schedule metformin administration infertile anovulatory PCOS patient .</brief_summary>
	<brief_title>Metformin Administration Infertile Anovulatory PCOS Patients</brief_title>
	<detailed_description>Infertile anovulatory PCOS eligible patient enrol randomly allocate receive tailor ( tailor group ) non-tailored metformin treatment ( non-tailored group ) . Tailored metformin treatment consist incremental dos regimen start dosage 850 mg daily ( one tablet daily ) weekly increase 2550 mg daily ( three tablet daily ) . The dosage metformin reduce accord appearance serous affect compliance drug-related side effect . Conversely , non-tailored metformin treatment consist fixed dos regimen 850 mg twice daily . For group , treatment six month . All patient eligible undergo baseline assessment consist anthropometric , hormonal , ultrasonographic evaluation . During study , clinical reproductive outcome , adverse experience evaluate patient . Data analyze use intention-to-treat principle P value 0.05 less consider significant . Continuous variable analyze unpaired test general linear model repeat measure analysis Bonferroni test post-hoc analysis require . For categorical variable , Pearson chi-square Fisher 's exact test use .</detailed_description>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Polycystic ovary syndrome ( use NIH criterion ) Anovulatory infertility ( use WHO criterion ) Age &lt; 18 &gt; 35 year Severe obesity ( BMI &gt; 35 ) Neoplastic , metabolic , hepatic , cardiovascular disorder concurrent medical illness Hypothyroidism , hyperprolactinemia , Cushing 's syndrome , nonclassical congenital adrenal hyperplasia Current previous ( within last six month ) use oral contraceptive , glucocorticoid , antiandrogens , antidiabetic antiobesity drug hormonal drug Previous use ovulation induction agent Intention start diet specific program physical activity Organic pelvic diseases Previous pelvic surgery Suspected peritoneal factor infertility Tubal male factor infertility subfertility</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Anovulation</keyword>
	<keyword>metformin</keyword>
	<keyword>PCOS</keyword>
	<keyword>treatment</keyword>
</DOC>